Rolf-Dieter AyeGerman, born in 1940
|
|
Pharma-Unternehmensberatung
Dr. R.-D. Aye
Reiherstieg 22
D-21337 Lüneburg | Germany
|
Tel.: ++49-4131-36725
Fax: ++49-4131-603250
E-Mail: aye@ayepartner.de
|
| |
| EDUCATION |
Profession: Pharmacist
Doctor of science (Dr. rer. nat.) in pharmaceutical chemistry from the university Tübingen, Germany 1967
|
| PROFESSIONAL
CURRICULUM |
1968 until 1972 Merck, Darmstadt, leader of a laboratory of the pharmaceutical development plant, especially occupied with the method techniques of the production of solid drugs
1972 to 1974 Dr. Thilo in Dortmund, head of quality control in pharmaceutical development, especially working in the fields of eye drugs and injection fluids
since 1974 head of Dr. Aye & Partner, consultant in all technical pharmaceutical affairs
in between 1983 and 1993 general manager of technical affairs of Lichtwer Pharma GmbH in Lüneburg and Berlin, responsible for development, production and quality control of drugs, regulatory and patent affairs
expert for pharmaceutical chemistry and drug registrations
since 1997 official external expert of the German Authority for Regulatory Affairs (BfArM) for the quality of herbal drugs and biopharmaceutical aspects
|
| FIELD OF
ACTIVITY |
Rolf-Dieter Aye is acting as an attested expert by the certification of pharmaceutical documentations for drug registrations and of pharmaceutical production plants in regard to the EU-Legislation and to GMP conformity.
Rolf-Dieter Aye advises besides his work as an expert several pharmaceutical companies concerning questions of pharmaceutical production and quality control and regulatory affairs. As a further activity Rolf-Dieter Aye is acting as a consulter in the conformity assessment procedure for medical devices.
He is member of the following scientific associations:
Society for Medicinal Plant and Natural Product Research
Deutsche Pharmazeutische Gesellschaft e.V.
He participated decisively in the planning and realisation of several new pharmaceutical plants, concerning mainly the production of solid drugs on a high technical level, corresponding to the GMP-rules, including the implementation of quality assurance systems.
|
| |
|
